Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Protocol and Population
2.2. Collection of Sociodemographic, Clinical, Lifestyle, and Anthropometric Data
2.3. Laboratory Determinations
2.4. Statistical Analysis
3. Results
3.1. Comparisons of Sociodemographic, Lifestyle, Clinical, and Laboratory Variables between Study Groups
3.2. Correlations of Omentin-1 with Metabolic, Tumor, Inflammatory, and Clinicopathologic Biomarkers
3.3. Independent Predictors of Circulating Omentin-1
3.4. Association of Omentin-1 with PBC Occurrence
3.5. Association of Circulating Omentin-1 with PBC Clinicopathologic Characteristics
3.6. Circulating Omentin-1 as a Biomarker in PBC
4. Discussion
- Omentin-1 exhibits pro-apoptotic actions in cancer cells (HepG2 and HuH-7 cells) as observed in hepatocellular carcinoma (HCC) via the activation of the JNK/p53/bcl-2/caspase-3 signaling pathway and the increase and stabilization of p21 and p53 proteins, the latter being a tumor suppressor protein [52]. In vitro studies have also shown that omentin-1 diminished the viability of prostate tumor cells, while knocking down omentin-1 augmented the proliferation of these cells [53].
- Omentin-1 presents tumor-suppressive, anti-proliferative, anti-invasive, and anti-metastatic potential. In gastric cancer cells, omentin-1 had a negative association with Ki67, an index of cell proliferation, and markers related to invasion and metastasis such as heparanase [54], while it inhibited the progression and metastasis of gastric cancer cells in vivo and in vitro [55]. Similar to our findings in BC, omentin-1 has been found to be inversely associated with tumor stage and lymph node infiltration in gastric cancer patients [54]. Both in vitro and in vivo studies have shown that omentin-1 may attenuate the aggressiveness of gastric cancer cells (invasion and metastasis) via suppression of the phosphoinositide 3-kinase (PI3K)/Akt/Nuclear factor-κΒ (NF-κB) signaling pathway [55]. Interestingly, omentin-1 may influence the growth and aggressiveness of neuroblastoma cells through the upregulation of the N-myc downstream regulated gene 2, which attenuates the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) [56].
- Omentin-1 has been reported to show anti-inflammatory properties via downregulation of the NF-κΒ signaling pathway, antagonism with the Toll-like receptor-4, and decreased expression of chemokines and cytokines (IL-6, TNF-α, etc.), and adhesion molecules [18]. This is in line with our study findings regarding the inverse relationship of omentin-1 with inflammatory biomarkers such as hsCRP, TNF-α, and IL-6.
- Finally, omentin-1 exerts beneficial metabolic properties through the enhancement of insulin’ s actions by activating glucose uptake in subcutaneous and omental fat cells [15], as well as through the prevention of glucose-induced endothelial dysfunction via the stimulation of the AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor δ (PPARδ) pathway [58].
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Siegel, R.L.; Torre, L.A.; Pearson-Stuttard, J.; Islami, F.; Fedewa, S.A.; Goding Sauer, A.; Shuval, K.; Gapstur, S.M.; Jacobs, E.J.; et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J. Clin. 2019, 69, 88–112. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Argyrakopoulou, G.; Dalamaga, M.; Spyrou, N.; Kokkinos, A. Gender differences in obesity-related cancers. Curr. Obes. Rep. 2021, 10, 100–115. [Google Scholar] [CrossRef]
- Daly, A.A.; Rolph, R.; Cutress, R.I.; Copson, E.R. A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer (Dove Med. Press) 2021, 13, 241–257. [Google Scholar] [CrossRef] [PubMed]
- Dorling, L.; Carvalho, S.; Allen, J.; González-Neira, A.; Luccarini, C.; Wahlström, C.; Pooley, K.A.; Parsons, M.T.; Fortuno, C.; Wang, Q.; et al. Breast cancer risk genes—Association analysis in more than 113,000 women. N. Engl. J. Med. 2021, 384, 428–439. [Google Scholar] [CrossRef] [PubMed]
- Christodoulatos, G.S.; Spyrou, N.; Kadillari, J.; Psallida, S.; Dalamaga, M. The role of adipokines in breast cancer: Current evidence and perspectives. Curr. Obes. Rep. 2019, 8, 413–433. [Google Scholar] [CrossRef] [PubMed]
- Avgerinos, K.I.; Spyrou, N.; Mantzoros, C.S.; Dalamaga, M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism 2019, 92, 121–135. [Google Scholar] [CrossRef] [PubMed]
- Guo, M.; Liu, T.; Li, P.; Wang, T.; Zeng, C.; Yang, M.; Li, G.; Han, J.; Wu, W.; Zhang, R. Association between metabolic syndrome and breast cancer risk: An updated meta-analysis of follow-up studies. Front. Oncol. 2019, 9, 1290. [Google Scholar] [CrossRef] [PubMed]
- Dalamaga, M. Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets. World J. Exp. Med. 2013, 3, 34–42. [Google Scholar] [CrossRef] [PubMed]
- Crujeiras, A.B.; Cabia, B.; Carreira, M.C.; Amil, M.; Cueva, J.; Andrade, S.; Seoane, L.M.; Pardo, M.; Sueiro, A.; Baltar, J.; et al. Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int. J. Obes. 2016, 40, 514–523. [Google Scholar] [CrossRef] [PubMed]
- Dalamaga, M.; Christodoulatos, G.S.; Liu, J. Diverting epithelial-to-mesenchymal transition to transform cancer cells to adipocytes: A promising strategy to stop metastasis. Metabol. Open 2019, 3, 100012. [Google Scholar] [CrossRef] [PubMed]
- Dalamaga, M.; Karmaniolas, K.; Papadavid, E.; Pelekanos, N.; Sotiropoulos, G.; Lekka, A. Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 2013, 20, 845–851. [Google Scholar] [CrossRef] [PubMed]
- Spyrou, N.; Avgerinos, K.I.; Mantzoros, C.S.; Dalamaga, M. Classic and novel adipocytokines at the intersection of obesity and cancer: Diagnostic and therapeutic strategies. Curr. Obes. Rep. 2018, 7, 260–275. [Google Scholar] [CrossRef] [PubMed]
- Yang, R.Z.; Lee, M.J.; Hu, H.; Pray, J.; Wu, H.B.; Hansen, B.C.; Shuldiner, A.R.; Fried, S.K.; McLenithan, J.C.; Gong, D.W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1253–E1261. [Google Scholar] [CrossRef]
- Jaikanth, C.; Gurumurthy, P.; Cherian, K.M.; Indhumathi, T. Emergence of omentin as a pleiotropic adipocytokine. Exp. Clin. Endocrinol. Diabetes 2013, 121, 377–383. [Google Scholar] [CrossRef] [PubMed]
- Schäffler, A.; Neumeier, M.; Herfarth, H.; Fürst, A.; Schölmerich, J.; Büchler, C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta 2005, 1732, 96–102. [Google Scholar] [CrossRef]
- Watanabe, T.; Watanabe-Kominato, K.; Takahashi, Y.; Kojima, M.; Watanabe, R. Adipose tissue-derived omentin-1 function and regulation. Compr. Physiol. 2017, 7, 765–781. [Google Scholar] [CrossRef]
- Cheng, X. Elucidating the pathophysiological significance of circulating omentin levels: Is higher better? Atherosclerosis 2016, 251, 522–524. [Google Scholar] [CrossRef]
- de Souza Batista, C.M.; Yang, R.Z.; Lee, M.J.; Glynn, N.M.; Yu, D.Z.; Pray, J.; Ndubuizu, K.; Patil, S.; Schwartz, A.; Kligman, M.; et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56, 1655–1661. [Google Scholar] [CrossRef]
- Tan, Y.L.; Zheng, X.L.; Tang, C.K. The protective functions of omentin in cardiovascular diseases. Clin. Chim. Acta 2015, 448, 98–106. [Google Scholar] [CrossRef] [PubMed]
- Arjmand, M.H.; Moradi, A.; Akbari, A.; Mehrad-Majd, H. Clinical significance of circulating omentin levels in various malignant tumors: Evidence from a systematic review and meta-analysis. Cytokine 2020, 125, 154869. [Google Scholar] [CrossRef] [PubMed]
- Cabia, B.; Andrade, S.; Carreira, M.C.; Casanueva, F.F.; Crujeiras, A.B. A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes. Rev. 2016, 17, 361–376. [Google Scholar] [CrossRef] [PubMed]
- Panagiotou, G.; Triantafyllidou, S.; Tarlatzis, B.C.; Papakonstantinou, E. Serum levels of irisin and omentin-1 in breast neoplasms and their association with tumor histology. Int. J. Endocrinol. 2021, 2021, 6656671. [Google Scholar] [CrossRef]
- Tahmasebpour, N.; Hosseinpour Feizi, M.A.; Ziamajidi, N.; Pouladi, N.; Montazeri, V.; Farhadian, M.; Abbasalipourkabir, R. Association of omentin-1 with oxidative stress and clinical significances in patients with breast cancer. Adv. Pharm. Bull. 2020, 10, 106–113. [Google Scholar] [CrossRef]
- Nourbakhsh, P.; Ganji, A.; Farahani, I.; Hosseinian, R.; Yeganefard, F.; Mirzaee, R.; Mosayebi, G. Adipokine Omentin-1: As a diagnostic tool in breast cancer. Int. J. Med. 2018, 3. [Google Scholar] [CrossRef]
- Alaee, M.; Farahani, H.; Mohaghegh, F. Circulating levels of omentin-1 in patients with breast cancer. Arch. Med. Lab. Sci. 2016, 2, 24–28. [Google Scholar] [CrossRef]
- Deurenberg, P.; Weststrate, J.A.; Seidell, J.C. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. Br. J. Nutr. 1991, 65, 105–114. [Google Scholar] [CrossRef] [PubMed]
- D’Agostino, R.B., Sr.; Vasan, R.S.; Pencina, M.J.; Wolf, P.A.; Cobain, M.; Massaro, J.M.; Kannel, W.B. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation 2008, 117, 743–753. [Google Scholar] [CrossRef] [PubMed]
- Carr, D.B.; Utzschneider, K.M.; Hull, R.L.; Kodama, K.; Retzlaff, B.M.; Brunzell, J.D.; Shofer, J.B.; Fish, B.E.; Knopp, R.H.; Kahn, S.E. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53, 2087–2094. [Google Scholar] [CrossRef]
- Capasso, I.; Esposito, E.; Pentimalli, F.; Crispo, A.; Montella, M.; Grimaldi, M.; De Marco, M.; Cavalcanti, E.; D’Aiuto, M.; Fucito, A.; et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol. Ther. 2010, 10, 1240–1243. [Google Scholar] [CrossRef]
- Agnoli, C.; Berrino, F.; Abagnato, C.A.; Muti, P.; Panico, S.; Crosignani, P.; Krogh, V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr. Metab. Cardiovasc. Dis. 2010, 20, 41–48. [Google Scholar] [CrossRef]
- Panagiotakos, D.B.; Pitsavos, C.; Arvaniti, F.; Stefanadis, C. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev. Med. 2007, 44, 335–340. [Google Scholar] [CrossRef]
- Dalamaga, M.; Muscogiuri, G.; Paganitsa, G.; Parvouleskou, G.; Syriou, V.; Karagkoynis, P.; Stratigou, T.; Vallianou, N.; Christodoulatos, G.S.; Karampela, I.; et al. Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: An observational cross-sectional study. Int. J. Food Sci. Nutr. 2021, 1–13. [Google Scholar] [CrossRef]
- Korovesi, A.; Dalamaga, M.; Kotopouli, M.; Papadavid, E. Adherence to the Mediterranean diet is independently associated with psoriasis risk, severity, and quality of life: A cross-sectional observational study. Int. J. Dermatol. 2019, 58, e164–e165. [Google Scholar] [CrossRef] [PubMed]
- Elliott, P.; Peakman, T.C. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 2008, 37, 234–244. [Google Scholar] [CrossRef] [PubMed]
- Sotiropoulos, G.P.; Dalamaga, M.; Antonakos, G.; Marinou, I.; Vogiatzakis, E.; Kotopouli, M.; Karampela, I.; Christodoulatos, G.S.; Lekka, A.; Papavassiliou, A.G. Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer. Lung Cancer 2018, 125, 291–299. [Google Scholar] [CrossRef]
- Stratigou, T.; Dalamaga, M.; Antonakos, G.; Marinou, I.; Vogiatzakis, E.; Christodoulatos, G.S.; Karampela, I.; Papavassiliou, A.G. Hyperirisinemia is independently associated with subclinical hypothyroidism: Correlations with cardiometabolic biomarkers and risk factors. Endocrine 2018, 61, 83–93. [Google Scholar] [CrossRef]
- Sotiropoulos, G.P.; Kotopouli, M.; Karampela, I.; Christodoulatos, G.S.; Antonakos, G.; Marinou, I.; Vogiatzakis, E.; Lekka, A.; Papavassiliou, A.G.; Dalamaga, M. Circulating plasminogen activator inhibitor-1 activity: A biomarker for resectable non-small cell lung cancer? J. Buon. 2019, 24, 943–954. [Google Scholar]
- Dalamaga, M.; Sotiropoulos, G.; Karmaniolas, K.; Pelekanos, N.; Papadavid, E.; Lekka, A. Serum resistin: A biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin. Biochem. 2013, 46, 584–590. [Google Scholar] [CrossRef] [PubMed]
- Hroussalas, G.; Kassi, E.; Dalamaga, M.; Delimaris, I.; Zachari, A.; Dionyssiou-Asteriou, A. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas 2008, 59, 339–349. [Google Scholar] [CrossRef] [PubMed]
- Karampela, I.; Kandri, E.; Antonakos, G.; Vogiatzakis, E.; Christodoulatos, G.S.; Nikolaidou, A.; Dimopoulos, G.; Armaganidis, A.; Dalamaga, M. Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: A prospective study. J. Crit. Care 2017, 41, 78–85. [Google Scholar] [CrossRef]
- Cook, F. Advanced Methods in Clinical Epidemiology; Harvard School of Public Health: Boston, MA, USA, 2000. [Google Scholar]
- Kawada, T. Circulating omentin level, obesity and cancer risk. Cytokine 2020, 130, 155083. [Google Scholar] [CrossRef] [PubMed]
- Shen, X.D.; Zhang, L.; Che, H.; Zhang, Y.Y.; Yang, C.; Zhou, J.; Liang, C.Z. Circulating levels of adipocytokine omentin-1 in patients with renal cell cancer. Cytokine 2016, 77, 50–55. [Google Scholar] [CrossRef] [PubMed]
- Heer, E.; Harper, A.; Escandor, N.; Sung, H.; McCormack, V.; Fidler-Benaoudia, M.M. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Glob. Health 2020, 8, e1027–e1037. [Google Scholar] [CrossRef]
- Le Marchand, L.; Wilkens, L.R.; Castelfranco, A.M.; Monroe, K.R.; Kristal, B.S.; Cheng, I.; Maskarinec, G.; Hullar, M.A.; Lampe, J.W.; Shepherd, J.A.; et al. Circulating biomarker score for visceral fat and risks of incident colorectal and postmenopausal breast cancer: The multiethnic cohort adiposity phenotype study. Cancer Epidemiol. Biomark. Prev. 2020, 29, 966–973. [Google Scholar] [CrossRef]
- Doyle, S.L.; Donohoe, C.L.; Lysaght, J.; Reynolds, J.V. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc. Nutr. Soc. 2012, 71, 181–189. [Google Scholar] [CrossRef]
- Powell-Wiley, T.M.; Poirier, P.; Burke, L.E.; Després, J.P.; Gordon-Larsen, P.; Lavie, C.J.; Lear, S.A.; Ndumele, C.E.; Neeland, I.J.; Sanders, P.; et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2021, 143, e984–e1010. [Google Scholar] [CrossRef]
- Booth, A.; Magnuson, A.; Fouts, J.; Foster, M. Adipose tissue, obesity and adipokines: Role in cancer promotion. Horm. Mol. Biol. Clin. Investig. 2015, 21, 57–74. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Y.; Zhang, B.; Hao, C.; Huang, X.; Li, X.; Huang, Y.; Luo, Z. Omentin-A novel adipokine in respiratory diseases. Int. J. Mol. Sci. 2017, 19, 73. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.Y.; Zhou, L.M. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur. J. Pharmacol. 2013, 698, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Mogal, A.P.; van der Meer, R.; Crooke, P.S.; Abdulkadir, S.A. Haploinsufficient prostate tumor suppression by Nkx3.1: A role for chromatin accessibility in dosage-sensitive gene regulation. J. Biol. Chem. 2007, 282, 25790–25800. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.; Weng, M.; Qi, M.; Qi, T.; Tong, L.; Hou, X.; Tong, Q. Aberrant expression of intelectin-1 in gastric cancer: Its relationship with clinicopathological features and prognosis. J. Cancer Res. Clin. Oncol. 2012, 138, 163–172. [Google Scholar] [CrossRef] [PubMed]
- Li, D.; Zhao, X.; Xiao, Y.; Mei, H.; Pu, J.; Xiang, X.; Jiao, W.; Song, H.; Qu, H.; Huang, K.; et al. Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer. Oncotarget 2015, 6, 16168–16182. [Google Scholar] [CrossRef] [PubMed]
- Li, D.; Mei, H.; Pu, J.; Xiang, X.; Zhao, X.; Qu, H.; Huang, K.; Zheng, L.; Tong, Q. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2. Mol. Cancer 2015, 14, 47. [Google Scholar] [CrossRef]
- Yin, L.; Huang, D.; Liu, X.; Wang, Y.; Liu, J.; Liu, F.; Yu, B. Omentin-1 effects on mesenchymal stem cells: Proliferation, apoptosis, and angiogenesis in vitro. Stem. Cell Res. Ther. 2017, 8, 224. [Google Scholar] [CrossRef]
- Liu, F.; Fang, S.; Liu, X.; Li, J.; Wang, X.; Cui, J.; Chen, T.; Li, Z.; Yang, F.; Tian, J.; et al. Omentin-1 protects against high glucose-induced endothelial dysfunction via the AMPK/PPARδ signaling pathway. Biochem. Pharmacol. 2020, 174, 113830. [Google Scholar] [CrossRef]
- Aleksandrova, K.; di Giuseppe, R.; Isermann, B.; Biemann, R.; Schulze, M.; Wittenbecher, C.; Fritsche, A.; Lehmann, R.; Menzel, J.; Weikert, C.; et al. Circulating omentin as a novel biomarker for colorectal cancer risk: Data from the EPIC-Potsdam Cohort Study. Cancer Res. 2016, 76, 3862–3871. [Google Scholar] [CrossRef]
- Uyeturk, U.; Sarıcı, H.; Kın Tekce, B.; Eroglu, M.; Kemahlı, E.; Uyeturk, U.; Gucuk, A. Serum omentin level in patients with prostate cancer. Med. Oncol. 2014, 31, 923. [Google Scholar] [CrossRef] [PubMed]
- Kiczmer, P.; Szydło, B.; Seńkowska, A.P.; Jopek, J.; Wiewióra, M.; Piecuch, J.; Ostrowska, Z.; Świętochowska, E. Serum omentin-1 and chemerin concentrations in pancreatic cancer and chronic pancreatitis. Folia. Med. Cracov. 2018, 58, 77–87. [Google Scholar] [CrossRef]
- Dalamaga, M.; Polyzos, S.A.; Karmaniolas, K.; Chamberland, J.; Lekka, A.; Migdalis, I.; Papadavid, E.; Dionyssiou-Asteriou, A.; Mantzoros, C.S. Circulating fetuin-A in patients with pancreatic cancer: A hospital-based case-control study. Biomarkers 2014, 19, 660–666. [Google Scholar] [CrossRef]
- Menzel, J.; di Giuseppe, R.; Biemann, R.; Wittenbecher, C.; Aleksandrova, K.; Pischon, T.; Fritsche, A.; Schulze, M.B.; Boeing, H.; Isermann, B.; et al. Omentin-1 and risk of myocardial infarction and stroke: Results from the EPIC-Potsdam cohort study. Atherosclerosis 2016, 251, 415–421. [Google Scholar] [CrossRef] [PubMed]
- Kataoka, Y.; Shibata, R.; Ohashi, K.; Kambara, T.; Enomoto, T.; Uemura, Y.; Ogura, Y.; Yuasa, D.; Matsuo, K.; Nagata, T.; et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J. Am. Coll Cardiol. 2014, 63, 2722–2733. [Google Scholar] [CrossRef]
- Maruyama, S.; Shibata, R.; Kikuchi, R.; Izumiya, Y.; Rokutanda, T.; Araki, S.; Kataoka, Y.; Ohashi, K.; Daida, H.; Kihara, S.; et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J. Biol. Chem. 2012, 287, 408–417. [Google Scholar] [CrossRef] [PubMed]
- Tan, B.K.; Adya, R.; Randeva, H.S. Omentin: A novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc. Med. 2010, 20, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Renehan, A.G.; Zwahlen, M.; Egger, M. Adiposity and cancer risk: New mechanistic insights from epidemiology. Nat. Rev. Cancer 2015, 15, 484–498. [Google Scholar] [CrossRef] [PubMed]
- Antonio de Luis, D.; Izaola, O.; Primo, D.; Aller, R. Modifications of serum levels of omentin-1 and other cardiovascular risk factors following weight loss secondary to a Mediterranean hypocaloric diet. Clin. Nutr. 2018, 37, 2280–2283. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Xue, J.; Hong, P. Relationships between serum omentin-1 concentration, body composition and physical activity levels in older women. Medicine 2021, 100, e25020. [Google Scholar] [CrossRef]
- Spyrou, N.; Vallianou, N.; Kadillari, J.; Dalamaga, M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Semin. Cancer Biol. 2021, 73, 356–376. [Google Scholar] [CrossRef] [PubMed]
- Rubinstein, M.M.; Brown, K.A.; Iyengar, N.M. Targeting obesity-related dysfunction in hormonally driven cancers. Br. J. Cancer 2021, 125, 495–509. [Google Scholar] [CrossRef]
- Trichopoulou, A.; Bamia, C.; Lagiou, P.; Trichopoulos, D. Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC (European Prospective Investigation into Cancer and Nutrition) cohort. Am. J. Clin. Nutr. 2010, 92, 620–625. [Google Scholar] [CrossRef] [PubMed]
- Panagiotakos, D.B.; Pitsavos, C.; Chrysohoou, C.; Skoumas, J.; Tousoulis, D.; Toutouza, M.; Toutouzas, P.; Stefanadis, C. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am. Heart J. 2004, 147, 106–112. [Google Scholar] [CrossRef]
- Watanabe, K.; Watanabe, R.; Konii, H.; Shirai, R.; Sato, K.; Matsuyama, T.A.; Ishibashi-Ueda, H.; Koba, S.; Kobayashi, Y.; Hirano, T.; et al. Counteractive effects of omentin-1 against atherogenesis†. Cardiovasc. Res. 2016, 110, 118–128. [Google Scholar] [CrossRef] [PubMed]
- Wittenbecher, C.; di Giuseppe, R.; Biemann, R.; Menzel, J.; Arregui, M.; Hoffmann, J.; Aleksandrova, K.; Boeing, H.; Isermann, B.; Schulze, M.B.; et al. Reproducibility of retinol binding protein 4 and Omentin-1 measurements over a four months period: A reliability study in a cohort of 207 apparently healthy participants. PLoS ONE 2015, 10, e0138480. [Google Scholar] [CrossRef] [PubMed]
Categorical/Ordinal Variables | A | B | C | D | p-Value | |
---|---|---|---|---|---|---|
PBC Patients (n = 103) n (%) | Controls (n = 103) n (%) | BBL Cases (n = 51) n (%) | PM Women with Obesity (n = 50) n (%) | All Groups | A vs. Β | |
Full-term pregnancies (n, %) | 0.03 | 0.05 | ||||
0 | 24 (23.3) | 14 (13.6) # | 6 (11.8) # | 2 (4) * | ||
1 | 13 (12.6) | 7 (6.7) | 5 (9.8) | 2 (4) | ||
2 | 54 (52.4) | 60 (58.3) | 31 (60.8) | 36 (72) | ||
≥3 | 12 (11.7) | 22 (21.4) | 9 (17.6) | 10 (20) | ||
Breast-feeding history (n, %) | 45 (43.7) | 52 (50.5) | 23 (45.1) | 24 (48) * | 0.04 | 0.18 |
Family history of breast cancer (n, %) | 14 (13.6) | 4 (3.9) * | 1 (2) * | 2 (4) # | 0.01 | 0.02 |
Family history of cancer (n, %) | 37 (35.9) | 15 (14.6) * | 8 (15.7) * | 4 (8) * | <0.001 | <0.001 |
Previous use of exogenous hormones (oral contraceptives and hormone therapy) (n, %) | 16 (15.5) | 5 (4.9) * | 4 (7.8) | 2 (4) * | 0.03 | 0.02 |
Physical activity (≥2 h/week) (n, %) | 4 (3.9) | 10 (9.7) # | 6 (11.8) # | 0 (0) | 0.03 | 0.09 |
Smoking history (n, %) | 0.32 | 0.26 | ||||
Non-smoker | 63 (61.2) | 74 (71.8) | 39 (76.5) | 30 (60) | ||
Ex-smoker | 8 (7.8) | 5 (4.9) | 2 (3.9) | 2 (4) | ||
Current smoker | 32 (31.1) | 24 (23.3) | 10 (19.6) | 18 (36) | ||
Passive smoking (n, %) | 59 (57.3) | 53 (51.5) | 23 (45.1) | 32 (64) | 0.23 | 0.40 |
Alcohol consumption (n, %) | 0.04 | 0.05 | ||||
0 glasses/typical day | 65 (63.1) | 81 (78.6) # | 32 (62.7) | 34 (68) | ||
1 glass/typical day | 28 (27.2) | 16 (15.5) | 18 (35.3) | 10 (20) | ||
2 glasses/typical day | 8 (7.8) | 6 (5.8) | 1 (2) | 6 (12) | ||
≥3 glasses/typical day | 2 (1.9) | 0 (0) | 0 (0) | 0 (0) | ||
Education (years) (n, %) | 0.001 | 0.07 | ||||
<6 | 8 (7.8) | 21 (20.4) # | 4 (7.8) | 6 (12) * | ||
6 | 27 (26.2) | 31 (30.1) | 16 (31.4) | 10 (20) | ||
9 | 29 (28.2) | 22 (21.4) | 9 (17.6) | 10 (20) | ||
12 | 23 (22.3) | 15 (14.6) | 15 (29.4) | 4 (8) | ||
>12 | 16 (15.5) | 14 (13.6) | 7 (13.7) | 20 (40) | ||
Metabolic syndrome (n, %) | 36 (35) | 24 (23.3) # | 13 (25.5) | 36 (72) * | <0.001 | 0.07 |
Grade of Mets (n, % from participants with Mets) | 0.04 | 0.09 | ||||
Low | 16 (44.4) | 16 (66.7) # | 9 (69.2) | 13 (36.1) | ||
High | 20 (55.6) | 8 (33.3) | 4 (30.8) | 23 (63.9) | ||
Diet variables | ||||||
Adherence to the Mediterranean diet (0–55) (n, %) | 0.07 | 0.01 | ||||
Low (0–20) | 5 (4.9) | 4 (3.9) * | 2 (3.9) * | 3 (6) | ||
Medium (21–35) | 91 (88.3) | 77 (74.8) | 38 (74.5) | 41 (82) | ||
High (36–55) | 7 (6.8) | 22 (21.4) | 11 (21.6) | 6 (12) | ||
Consumption of olive oil in cooking (times per week) (n, %) | <0.001 | <0.001 | ||||
Never | 0 (0) | 0 (0) * | 0 (0) * | 0 (0) | ||
Rarely | 1 (1) | 1 (1) | 1 (2) | 0 (0) | ||
<1 | 23 (22.3) | 5 (4.9) | 6 (11.8) | 8 (16) | ||
1–3 | 56 (54.4) | 36 (35) | 21 (41.2) | 22 (44) | ||
3–5 | 18 (17.5) | 41 (39.8) | 17 (33.3) | 14 (28) | ||
Daily | 5 (4.9) | 20 (19.4) | 6 (11.8) | 6 (12) | ||
Consumption of red meat (servings per week) (n, %) | 0.26 | 0.01 | ||||
≤1 | 10 (9.7) | 29 (28.2) * | 12 (23.5) | 9 (18) | ||
2–3 | 59 (57.3) | 52 (50.5) | 28 (54.9) | 27 (54) | ||
4–5 | 23 (22.3) | 16 (15.5) | 8 (15.7) | 10 (20) | ||
6–7 | 10 (9.7) | 5 (4.9) | 2 (3.9) | 3 (6) | ||
8–10 | 1 (1) | 1 (1) | 1 (2) | 1 (2) | ||
>10 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Consumption of vegetables (servings per week) (n, %) | 0.41 | 0.04 | ||||
0 | 3 (2.9) | 1 (1) * | 1 (2) | 1 (2) | ||
1–6 | 81 (78.6) | 65 (63.1) | 32 (62.7) | 36 (72) | ||
7–12 | 18 (17.5) | 31 (30.1) | 16 (31.4) | 12 (24) | ||
13–20 | 1 (1) | 5 (4.9) | 2 (3.9) | 1 (2) | ||
21–32 | 0 (0) | 1 (1) | 0 (0) | 0 (0) | ||
>33 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Consumption of fruits (servings per week) (n, %) | 0.26 | 0.04 | ||||
0 | 2 (1.9) | 1 (1) * | 1 (2) | 1 (2) | ||
1–4 | 34 (33) | 16 (15.5) | 9 (17.6) | 9 (18) | ||
5–8 | 55 (53.4) | 65 (63.1) | 30 (58.8) | 34 (68) | ||
9–15 | 11 (10.7) | 19 (18.4) | 10 (19.6) | 6 (12) | ||
16–21 | 1 (1) | 2 (1.9) | 1 (2) | 0 (0) | ||
Clinicopathologic variables | ||||||
Stage (n, %) | - | - | - | - | - | |
I | 40 (38.8) | |||||
II | 31 (30.1) | |||||
III | 16 (15.5) | |||||
IV | 16 (15.5) | |||||
Grade (n, %) | - | - | - | - | - | |
I/II | 61 (59.2) | |||||
III | 42 (40.8) | |||||
Tumor size (n, %) | - | - | - | - | - | |
<2 cm | 45 (43.7) | |||||
≥2 cm | 58 (56.3) | |||||
Lymph node involvement (n, %) | - | - | - | - | - | |
0 | 23 (22.3) | |||||
1 | 45 (43.7) | |||||
≥2 | 35 (34) | |||||
Hormone receptor status (n, %) | - | - | - | - | - | |
ER+ | 78 (75.7) | |||||
PR+ | 57 (55.3) | |||||
ER+ PR+ | 55 (53.4) | |||||
ER− PR− | 24 (23.3) | |||||
Continuous Variables | A | B | C | D | p-Value | |
PBC Patients (n = 103) Mean (SD) | Controls (n = 103) Mean (SD) | BBL Cases (n = 51) Mean (SD) | PM Women with Obesity (n = 50) Mean (SD) | All Groups | A vs. B | |
Age, years | 61.5 (8.2) | 62.3 (8.8) | 63.1 (9.6) | 61.1 (9.3) | 0.52 | 0.3 |
Reproductive Variables | ||||||
Age at menarche (years) | 12.2 (1.2) | 12.6 (1.2) * | 12.61 (0.9) | 12.9 (1) * | 0.002 | 0.04 |
Age at menopause (years) | 49.3 (2.9) | 48.5 (3.5) # | 48.6 (3.2) | 49.6 (2.8) | 0.11 | 0.06 |
Years with menstruation | 37.1 (3.2) | 35.9 (3.8) * | 35.9 (3.3) * | 36.6 (2.9) | 0.06 | 0.02 |
Time since menopause (years) | 12.3 (8) | 14 (9.5) # | 14.3 (9.7) | 11.5 (9.7) | 0.15 | 0.09 |
Age at first full-term pregnancy (years) | 28.6 (4.8) | 27.3 (5.3) # | 27.5 (5.4) | 25.7 (4.7) * | 0.02 | 0.09 |
Somatometric Variables | ||||||
Weight, kg | 73.9 (11) | 68.1 (13) * | 67.7 (11.6) * | 88.6 (14.1) * | <0.001 | 0.001 |
Height, m | 1.63 (0.06) | 1.62 (0.05) # | 1.62 (0.05) | 1.59 (0.04) * | <0.001 | 0.06 |
BMI, kg/m2 | 27.7 (4.14) | 25.9 (5.4) * | 25.7 (4.4) * | 35.1 (6) * | <0.001 | 0.012 |
Waist circumference, cm | 85.1 (10) | 82.3 (10.9) # | 84.2 (10.9) | 103 (8.6) * | <0.001 | 0.06 |
Fat mass, % | 42 (5.3) | 40.2 (6.7) * | 39.9 (5.7) * | 50.7 (7.7) * | <0.001 | 0.04 |
Fat mass, kg | 31.5 (8.5) | 28.2 (11.5) * | 27.6 (9.3) * | 45.9 (15.2) * | <0.001 | 0.02 |
Blood pressure variables | ||||||
SBP, mmHg | 139.7 (17.6) | 135.5 (13.5) # | 139.2 (19.8) | 135.1 (18.2) * | 0.19 | 0.08 |
DBP, mmHg | 82.1 (11.5) | 82.3 (9.9) | 82.8 (11.1) | 83.2 (11.3) * | 0.94 | 0.11 |
Mean arterial BP ∂, mmHg | 99 (6.2) | 97.2 (7.5) # | 97.9 (8.5) | 103.9 (8.9) * | <0.001 | 0.06 |
MedDiet score | 26.4 (5.3) | 32.6 (5.7) * | 32.9 (5.2) * | 27.4 (7.1) | <0.001 | <0.001 |
Metabolic biomarkers | ||||||
Glucose, mmol/L (Ref. range: 4.11–5.88) | 5.42 (0.89) | 5.14 (0.88) * | 5.18 (0.72) # | 6.36 (0.92) * | <0.001 | 0.02 |
Insulin, pmol/L (Ref. range: 18.06–172.93) | 82.6 (78.5) | 65.3 (45.1) # | 68.1 (35.4) | 109 (54.9) * | <0.001 | 0.05 |
HOMA-IR score | 3.1 (3.7) | 2.3 (2.2) # | 2.3 (1.5) # | 4.6 (3.1) * | <0.001 | 0.05 |
Lipid biomarkers and CVD risk | ||||||
Total cholesterol, mmol/L (Ref. range: 3.62–5.69) | 5.32 (0.7) | 5.01 (0.66) * | 5.06 (0.74) * | 5.65 (1.03) * | <0.001 | 0.001 |
Triglycerides, mmol/L (Ref. range: <2.26) | 1.35 (0.43) | 1.18 (0.44) * | 1.25 (0.42) | 1.77 (0.33) * | <0.001 | 0.005 |
HDL-C, mmol/L (Ref. range ♀: 1.16–1.68) | 1.31 (0.15) | 1.41 (0.12) * | 1.37 (0.14) * | 1.25 (0.11) * | <0.001 | <0.001 |
LDL-C, mmol/L (Ref. range: <4.11) | 3.4 (0.65) | 3.06 (0.62) * | 3.12 (0.71) * | 3.6 (0.99) | <0.001 | <0.001 |
Framingham score, % | 10.9 (5.3) | 9.3 (5.1) * | 10.1 (7.3) | 13.1 (7.5) # | 0.003 | 0.03 |
Tumor biomarkers | ||||||
CA 15-3, kU/L (Ref. range: <25) | 110.3 (158.1) | 17.7 (8.3) * | 18.4 (9.3) * | 17.5 (9) * | <0.001 | <0.001 |
CEA, μg/L (Ref. range: <3.8 in NS <5.5 in S) | 12.3 (24.6) | 1.9 (1.04) * | 1.9 (1.05) * | 1.6 (0.9) * | <0.001 | <0.001 |
Inflammatory biomarkers | ||||||
hsCRP, nmol/L (Ref. range: <47.62) | 47.81 (46) | 18.95 (17.05) * | 19.81 (12.10) * | 40 (20.95) | <0.001 | <0.001 |
TNF-α, ng/L (Ref. range: <8) | 23.66 (11.4) | 10.35 (4.93) * | 10.11 (4.34) * | 14.8 (4.6) * | <0.001 | <0.001 |
IL-6, ng/L (Ref. range: <7) | 18.28 (11.39) | 8.68 (4.78) * | 8.53 (4.94) * | 14.1 (5.5) * | <0.001 | <0.001 |
Adipokines | ||||||
Leptin, μg/L | 28.8 (17.2) | 27.8 (17.5) | 27.2 (17.8) | 43.3 (23.4) * | 0.001 | 0.7 |
Adiponectin, mg/L | 16.9 (9.8) | 19.8 (10.1) * | 18.9 (7.9) | 18.5 (8.4) | 0.53 | 0.04 |
Omentin-1, μg/L | 340.5 (109.3) | 476.7 (156.1) * | 455.4 (65.9) * | 363.9 (104.4) | <0.001 | <0.001 |
Variables | PBC Patients (n = 103) | Controls (n = 103) | BBL Cases (n = 51) | PM Women with Obesity (n = 50) | ||||
---|---|---|---|---|---|---|---|---|
r | p | r | p | r | p | r | p | |
Smoking history | −0.05 | 0.59 | 0.02 | 0.83 | 0.05 | 0.75 | 0.40 | 0.004 |
Alcohol consumption | −0.004 | 0.97 | −0.03 | 0.79 | −0.18 | 0.21 | 0.10 | 0.48 |
Consumption of olive oil | 0.52 | <0.001 | 0.35 | <0.001 | 0.43 | 0.002 | 0.69 | <0.001 |
Consumption of red meat | −0.25 | 0.01 | −0.60 | <0.001 | −0.65 | <0.001 | −0.70 | <0.001 |
Consumption of vegetables | 0.43 | <0.001 | 0.61 | <0.001 | 0.64 | <0.001 | 0.62 | <0.001 |
Consumption of fruits | 0.49 | <0.001 | 0.53 | <0.001 | 0.69 | <0.001 | 0.74 | <0.001 |
Somatometric Variables | ||||||||
BMI | −0.28 | 0.004 | −0.47 | <0.001 | −0.48 | <0.001 | −0.44 | 0.001 |
Waist circumference | −0.29 | 0.003 | −0.49 | <0.001 | −0.50 | <0.001 | −0.34 | 0.02 |
Fat % | −0.24 | 0.02 | −0.43 | <0.001 | −0.52 | <0.001 | −0.58 | <0.001 |
Fat mass | −0.27 | 0.006 | −0.43 | <0.001 | −0.53 | <0.001 | −0.54 | <0.001 |
Blood pressure indices | ||||||||
SBP | −0.40 | <0.001 | −0.36 | <0.001 | −0.55 | <0.001 | −0.47 | 0.001 |
DBP | −0.27 | 0.006 | −0.46 | <0.001 | −0.66 | <0.001 | −0.45 | 0.001 |
Mean arterial BP | −0.38 | <0.001 | −0.45 | <0.001 | −0.61 | <0.001 | −0.49 | <0.001 |
MedDiet score | 0.65 | <0.001 | 0.66 | <0.001 | 0.70 | <0.001 | 0.78 | <0.001 |
Metabolic biomarkers | ||||||||
Glucose | −0.26 | 0.01 | −0.55 | <0.001 | −0.28 | 0.04 | −0.54 | <0.001 |
Insulin | −0.21 | 0.04 | −0.52 | <0.001 | −0.39 | 0.004 | −0,39 | 0.005 |
HOMA-IR | −0.23 | 0.02 | −0.54 | <0.001 | −0.37 | 0.008 | −0.47 | 0.001 |
Lipid biomarkers and CVD risk | ||||||||
Total cholesterol | −0.32 | 0.001 | −0.40 | <0.001 | −0.53 | <0.001 | −0.60 | <0.001 |
Triglycerides | −0.37 | <0.001 | −0.52 | <0.001 | −0.64 | <0.001 | −0,45 | 0.001 |
HDL-C | 0.35 | <0.001 | 0.46 | <0.001 | 0.57 | <0.001 | 0.33 | 0.02 |
LDL-C | −0.31 | 0.001 | −0.32 | 0.001 | −0.47 | 0.001 | −0.58 | <0.001 |
Framingham score, % | −0.32 | 0.001 | −0.28 | 0.004 | −0.51 | <0.001 | −0.56 | <0.001 |
Tumor biomarkers | ||||||||
CA15-3 | −0.39 | <0.001 | 0.08 | 0.41 | 0.05 | 0.72 | 0.12 | 0.42 |
CEA | −0.31 | 0.002 | −0.05 | 0.64 | −0.03 | 0.86 | 0.12 | 0.42 |
Inflammatory biomarkers | ||||||||
hsCRP | −0.56 | <0.001 | −0.49 | <0.001 | −0.38 | 0.006 | −0.39 | 0.005 |
TNF-α | −0.51 | <0.001 | −0.50 | <0.001 | −0.23 | 0.10 | −0.39 | 0.005 |
IL-6 | −0.47 | <0.001 | −0.54 | <0.001 | −0.10 | 0.50 | −0.18 | 0.20 |
Adipokines | ||||||||
Leptin | −0.001 | 0.99 | −0.27 | 0.006 | −0.34 | 0.02 | −0.22 | 0.13 |
Adiponectin | −0.02 | 0.82 | 0.21 | 0.03 | 0.45 | 0.001 | 0.26 | 0.07 |
Clinicopathologic features | ||||||||
Stage | −0.45 | <0.001 | - | - | - | - | - | - |
Number of infiltrated lymph nodes | −0.48 | <0.001 | - | - | - | - | - | - |
Model A in Patients with Postmenopausal Breast Cancer (n = 103) | Model B in Controls, Cases with BBL, and Postmenopausal Women with Obesity (n = 204) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Independent Variables | b | SEb | t Statistic | p-Value | Independent Variables | b | SEb | t Statistic | p-Value |
Adherence to the Mediterranean diet | 98.10 | 31.43 | 3.12 | 0.002 | Adherence to the Mediterranean diet | 96.44 | 14.60 | 6.61 | <0.001 |
Adiponectin (mg/L) | 2.56 | 1.01 | 2.53 | 0.013 | Adiponectin (mg/L) | 2.12 | 0.73 | 2.89 | 0.004 |
Mean arterial BP (mmHg) | −3.85 | 1.79 | −2.15 | 0.03 | Mean arterial BP (mmHg) | −2.39 | 0.97 | −2.47 | 0.014 |
hsCRP (nmol/L) | −11.58 | 2.71 | −4.27 | <0.001 | IL-6 (ng/L) | −3.36 | 1.36 | −2.47 | 0.014 |
CA 15-3 (kU/L) | 0.28 | 0.08 | 3.42 | 0.001 | Fat mass (%) | −3.44 | 1.08 | −3.19 | 0.002 |
Serum Omentin-1 (μg/L) | Category or Increment | Crude OR (95% CI) | p-Value | Adjusted OR a (95% CI) | p-Value |
---|---|---|---|---|---|
As compared with controls | |||||
Omentin-1 in quartiles | 1 quartile more | 0.08 (0.04–0.16) | <0.001 | 0.006 (0.001–0.04) | <0.001 |
Omentin-1 (continuous variable) | 1 μg/L of omentin-1more | 0.98 (0.97–0.98) | <0.001 | 0.98 (0.97–0.99) | <0.001 |
Omentin-1 SD | 1 SD unit of omentin-1 more | 0.03 (0.01–0.07) | <0.001 | 0.01 (0.003–0.05) | <0.001 |
As compared with controls, BBL cases, and PM participants with obesity | |||||
Omentin-1 in quartiles | 1 quartile more | 0.23 (0.16–0.32) | <0.001 | 0.04 (0.02–0.09) | <0.001 |
Omentin-1 (continuous variable) | 1 μg/L of omentin-1 more | 0.99 (0.98–0.99) | <0.001 | 0.98 (0.97–0.98) | <0.001 |
Omentin-1 in SD | 1 SD unit of omentin-1 more | 0.09 (0.05–0.18) | <0.001 | 0.01 (0.003–0.04) | <0.001 |
Clinicopathologic Features | Serum Omentin-1, μg/L (Mean ± SD) | p-Value |
---|---|---|
Stage | 0.012 | |
I | 369.1 ± 123.9 | |
II | 331.3 ± 17.3 | |
III | 267.1 ± 41.7 | |
IV | 358.4 ± 169.4 | |
Grade | 0.10 | |
I/II | 355.1 ± 102.4 | |
III | 319.3 ± 116.7 | |
Tumor size | 0.06 | |
<2 cm | 362.7 ± 118.4 | |
≥2 cm | 323.2 ± 99.3 | |
Lymph node involvement | 0.04 | |
0 | 388.9 ± 160.5 | |
1 | 335 ± 21.3 | |
≥2 | 315.6 ± 127.8 | |
ER status | 0.03 | |
Positive | 349.3 ± 122.2 | |
Negative | 312.9 ± 42.7 | |
PR status | 0.12 | |
Positive | 354.4 ± 141.2 | |
Negative | 323.2 ± 41.7 | |
ERPR status | 0.14 | |
Both positive | 354.6 ± 143.7 | |
Other types | 324.2 ± 41.3 | |
ERPR status | 0.02 | |
Both negative | 311.2 ± 42.5 | |
Other types | 349.3 ± 121.5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Christodoulatos, G.S.; Antonakos, G.; Karampela, I.; Psallida, S.; Stratigou, T.; Vallianou, N.; Lekka, A.; Marinou, I.; Vogiatzakis, E.; Kokoris, S.; et al. Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study. Biomolecules 2021, 11, 1609. https://doi.org/10.3390/biom11111609
Christodoulatos GS, Antonakos G, Karampela I, Psallida S, Stratigou T, Vallianou N, Lekka A, Marinou I, Vogiatzakis E, Kokoris S, et al. Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study. Biomolecules. 2021; 11(11):1609. https://doi.org/10.3390/biom11111609
Chicago/Turabian StyleChristodoulatos, Gerasimos Socrates, Georgios Antonakos, Irene Karampela, Sotiria Psallida, Theodora Stratigou, Natalia Vallianou, Antigoni Lekka, Ioanna Marinou, Evaggelos Vogiatzakis, Styliani Kokoris, and et al. 2021. "Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study" Biomolecules 11, no. 11: 1609. https://doi.org/10.3390/biom11111609